We’re lowering our fair value estimate for Procter & Gamble due to the negative impact of currencies, but the firm’s underlying business is gaining traction and shares look modestly undervalued.
Oil and gas weakness is offset by the rest of the portfolio in the fourth quarter.
Despite an improving pipeline and slowing patent losses, a lackluster growth outlook will likely drive Pfizer to acquire assets in the near term.
The firm's shift to a cloud, mobile, and services model progresses, while the core commercial business--last quarter's difficult comparisons aside--remains solid.
The firm's diversified industrial portfolio delivered a solid quarter of growth as ongoing momentum in several U.S. end markets more than offset weakness in energy.
With an improving pipeline and a new manufacturing technology, Amgen is on the path to stabilizing its moat trend.
We expect to raise our fair value estimates but don't anticipate changing either company's no- moat rating following news of the deal.
We like wide - moat Intel's long-term positioning, but investors should seek a wider margin of safety before buying, writes Morningstar's Peter Wahlstrom.
Earnings reports this week showed how Netflix, IBM, Microsoft, and eBay are thinking about their futures. Plus: Europe's QE is no cure-all.
Our most popular articles and videos for the week ended January 23.